

**FAX CAPITAL CORP.
MANAGEMENT DISCUSSION AND ANALYSIS
FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2021**

This Management Discussion and Analysis (“MD&A”) should be read in conjunction with the audited financial statements of FAX Capital Corp. (the “Company”) for the year ended December 31, 2020 and the related notes. The Company’s reporting currency is the Canadian dollar and all amounts in this MD&A are expressed in Canadian dollars. This MD&A is prepared as of November 4, 2021.

The financial information of the Company within this MD&A is derived from the financial statements of the Company as at and for the nine months ended September 30, 2021 prepared in accordance with International Financial Reporting Standards (“IFRS”) accounting policies as issued by the International Accounting Standards Board IASB.

Additional information relating to the Company, including the Company’s most recent financial statements and Annual Information Form, is available at www.sedar.com. Additional information can also be accessed from the Company’s website at www.faxcapitalcorp.com.

BUSINESS PROFILE

FAX Capital Corp. is an investment holding company. The Company invests in equity, debt and/or hybrid securities of high-quality public and private businesses, with a goal of building long-term wealth for shareholders. Our subordinate voting shares and Founder Warrants trade on the Toronto Stock Exchange (the “TSX”) under the symbol “FXC” and “FXC.WT”, respectively. The Company’s multiple voting shares are not listed on any exchange. As used herein, the term “shares” or “common shares” refers collectively to both the Company’s multiple voting shares and subordinate voting shares.

FORWARD-LOOKING STATEMENTS

Certain statements contained in this MD&A constitute “forward-looking statements” within the meaning of applicable securities laws. Forward-looking statements may relate to the Company’s future outlook and anticipated events or results and may include statements regarding the financial position, business strategy, growth strategy, budgets, operations, financial results, taxes, dividends, plans and objectives of the Company. Particularly, statements regarding future results, performance, achievements, prospects or opportunities of the Company are forward-looking statements. In some cases, forward-looking statements can be identified by the use of forward-looking terminology such as “plans”, “expects” or “does not expect”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates” or “does not anticipate” or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might”, “will” or “will be taken”, “occur” or “be achieved”. Forward-looking information in this MD&A includes, but is not limited to, statements regarding: the Company’s investment approach, objectives and strategy, including investment selection; the structuring of its investments; its plans to manage its investments; and the Company’s financial performance.

Forward-looking statements are based on the opinions and estimates of the Company as of the date of this MD&A, and they are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, level of activity, performance or achievements to be materially different from those expressed or implied by such forward-looking statements, including but not limited to the following factors which are contained in the Company’s management discussion and analysis for the year-ended December 31, 2020: potential lack of investment diversification; pace of completing investments; financial market fluctuations and deterioration of political conditions; key employees; reliance on the performance of underlying assets; investments in private issuers; illiquid assets; competitive market for investment opportunities; competition and technology risks; credit risk; tax

risks; regulatory changes and foreign security risk. Additional information about these and other risks and uncertainties of the Company's business are described in the Company's most recent Annual Information Form dated March 25, 2021, which is available at www.sedar.com and on the Company's website at www.faxcapitalcorp.com.

Although the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements, particularly in light of the ongoing and developing COVID-19 pandemic and its impact on the global economy and its uncertain future impact on the Company's operations and its portfolio companies. Accordingly, readers should not place undue reliance on forward-looking statements. The Company does not undertake to update any forward-looking statements contained herein, except as required by applicable securities laws. New factors emerge from time to time, and it is not possible for the Company to predict all of these factors or to assess in advance the impact of each such factor on the Company's business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statement.

USE OF NON-IFRS FINANCIAL MEASURES

This MD&A makes reference to the following financial measure which is not recognized under International Financial Reporting Standards ("IFRS") and which does not have a standard meaning prescribed by IFRS: "book value per share".

The Company's book value per share is a measure of the performance of the Company as a whole. Book value per share is measured by dividing shareholders' equity of the Company at the date of the statement of financial position by the number of shares outstanding at that date.

The Company's method of determining this financial measure may differ from other companies' methods and, accordingly, this amount may not be comparable to measures used by other companies. This financial measure is not a performance measure as defined under IFRS and should not be considered either in isolation of, or as a substitute for, net earnings prepared in accordance with IFRS.

DEVELOPMENT OF THE BUSINESS

On November 21, 2019, the Company closed a public offering (the "Offering") of units of the Company ("Units"). Each Unit consisted of one subordinate voting share of the Company and one subordinate voting share purchase warrant (a "Founder Warrant"). An aggregate of 15,560,000 Units were issued by the Company at the offering price of \$4.50 per Unit for aggregate gross proceeds of \$70.0 million. Also on November 21, 2019, the Company closed the purchase by Fax Investments Inc. ("Fax Investments"), on a private placement basis, of 26,671,110 multiple voting shares for aggregate gross proceeds of \$120.0 million. Fax Investments did not receive any Founder Warrants as part of its subscription for multiple voting shares. The aggregate gross proceeds of the Offering and the private placement (collectively, the "Offerings") was \$190.0 million.

STRATEGY OVERVIEW

The following description is an overview of the Company's investment strategy:

- We intend to invest in approximately 10 to 15 high-quality small cap public and private businesses located primarily in Canada and, to a lesser extent, the United States.
- We anticipate taking meaningful and influential stakes in carefully selected public companies that have the potential to significantly improve the fundamental value of their business over the long-term. We target small cap businesses with a market capitalization of between \$15 million and \$1.5 billion.
- We anticipate taking meaningful positions or control of select private company investments, where we will seek to enhance returns and provide our shareholders with a unique opportunity to obtain exposure to high-quality private businesses with enterprise values in the range of \$15 million to \$250 million.
- Our ownership position in a portfolio company may range from a minority ownership position to a significant influence position including, in some instances, control.
- We intend to use our ownership position to support our portfolio company's growth and development through active ownership. The support we extend to our portfolio companies may be provided by way of board representation, board observer rights, strategic, financial, governance and capital market support.
- We are long-term investors in businesses and operate with a permanent capital base which enables us to provide long-term stable capital to our portfolio companies, and to remain patient to maximize the power of compounding.

INVESTMENT RESTRICTIONS

On May 19, 2021, at the Company's annual general and special meeting of shareholders, the shareholders approved a further amendment and restatement of the Company's Amended and Restated Voluntary Measures By-Law (the "A&R Voluntary Measures By-Law") in order to remove the Investment Concentration Restriction. Additionally, the Company will no longer be adhering to the original stated investment allocation objective of investing between 60-80% of the Net Proceeds of the Offerings in public investments, with the remainder invested in private investments. The Company, however, is committed to invest at least 75% of the Net Proceeds of the Offerings on or before November 21, 2022, except where the Company's board of directors (the "Board") determines, acting reasonably and in good faith, that satisfying such commitment would result in a breach of the Board's fiduciary duties under applicable corporate law. Pending deployment of investment into portfolio companies, the Company will invest of the Net Proceeds of the Offerings in liquid and low risk securities.

COVID-19 PANDEMIC

COVID-19 was declared a pandemic by the World Health Organization in early 2020. While some regions of the world have started to roll back the emergency measures they enacted to combat the spread of COVID-19, the overall impact of the COVID-19 pandemic is still uncertain and dependent on the progression of the virus and on actions taken by governments, businesses and individuals, which could vary by country and result in differing outcomes. While the deterioration in economic conditions and reduction in valuations for some businesses may result in acquisition opportunities for the Company, COVID-19 may present challenges for its investee companies and may make it more difficult for the Company to deploy capital and complete investments. Further challenges could include delayed due diligence on target companies due to international or domestic travel restrictions or obtaining onsite access to target companies' facilities or physical books and records due to lockdown measures. Additionally, any target business that the Company identifies that has been required to reduce or suspend business operations for a period of time due to COVID-19 may be subject to increased business, employment, operating and financial risks.

The COVID-19 pandemic has also led to higher valuations for certain businesses that have shown to be resilient to the above-mentioned impacts of COVID-19 or which, in some cases, have benefited from the COVID-19 pandemic. To the extent that the Company seeks to make investments in these businesses, it may be required to pay a higher purchase price or may face increased competition from other investors looking to acquire such businesses.

The continuing or worsening of the economic and market conditions caused by the COVID-19 pandemic, and its impact on the economy could have a material adverse effect on the Company's business, including on the valuation of its investee companies and the Company's financial condition. Further information about the impact and their response to the pandemic can be accessed from each of the Company's investee company websites or, if applicable, from their continuous disclosure documents at www.sedar.com.

To the extent the COVID-19 pandemic adversely impacts the Company's and its investee companies' business, results of operations and financial condition, it may also have the effect of heightening many of the other risks described or referenced in this document or in the Company's most recent Annual Information Form.

Even though progress has been made on the deployment of vaccines, the duration and full impact of the COVID-19 pandemic is unknown at this time, as is the efficacy of the government and central bank interventions. As a result, it is not possible to reliably estimate the length and severity of these developments and the impact on the financial results and condition of the Company in future periods. In response to the impact of COVID-19, the Company has implemented its business continuity plan, which has included moving all employees to work from home.

COVID-19 has the current and ongoing potential to expose the Company to a number of risks inherent in our business activities. These include: pace of completing investments, financial market fluctuations and deterioration of political and economic conditions, and competitive market for investment opportunities. These risks are discussed in further detail in the Company's most recent Annual Information Form, dated March 25, 2021, which is available on www.sedar.com and on the Company's website at www.faxcapitalcorp.com.

SUMMARY OF INVESTMENT PORTFOLIO

The Company held the following investments as at September 30, 2021:

Table 1: Schedule of Investment Portfolio as at September 30, 2021

(\$ thousands)				% of Portfolio
Description	Number of securities	Cost	Fair Value	Fair Value
Public company investments				
Information Services Corporation	1,074,967	16,317	29,734	12.9%
Hamilton Thorne Ltd.	17,495,500	21,600	31,667	13.8%
Points International Ltd.	1,032,155	20,066	22,367	9.7%
Quisitive Technology Solutions Inc. (i)	19,333,333	25,000	24,606	10.7%
BioSynt Inc.	2,121,100	15,348	15,060	6.5%
Avante Logixx Inc.	2,000,000	3,500	4,180	1.8%
Other (ii)		7,636	10,669	4.6%
Private company investments				
Carson, Dunlop & Associates Ltd. (iii)		12,884	13,400	5.8%
Cash and cash equivalents		78,261	78,261	34.0%
		200,611	229,944	100.0%

(i) Includes 16,000,000 common shares, purchased under a private placement arrangement that are subject to a 12 month hold period from the transaction close date of March 22, 2021.

(ii) Other includes common shares of a Canadian public company in which the Company is in the process of accumulating its targeted position.

(iii) The Company's investment in Carson, Dunlop & Associates Ltd. is held in its majority owned subsidiary 2794677 Ontario Corp.

A summary of changes in the fair value of the Company's investment portfolio for the three and nine month periods ended September 30, 2021 is as follows:

Table 2: Summary of Changes in the Company's Investment Portfolio

(\$ thousands)	Three Months Ended September 30, 2021				Nine Months Ended September 30, 2021					
	Balance as of Jul. 1, 2021	Purchases	Net change in unrealized gains (losses) on investments	Balance as of Sep. 30, 2021	Balance as of Jan. 1, 2021	Purchases	Sales	Realized gains on sale of investments	Net change in unrealized gains (losses) on investments	Balance as of Sep. 30, 2021
Public company investments										
Information Services Corporation	32,787	-	(3,053)	29,734	20,688	785	-	-	8,261	29,734
Hamilton Thorne Ltd.	34,710	1,260	(4,303)	31,666	22,259	3,065	-	-	6,343	31,666
Points International Ltd.	22,191	-	175	22,367	18,234	1,001	-	-	3,131	22,367
People Corporation	-	-	-	-	27,391	-	27,700	13,538	(13,229)	-
Quisitive Technology Solutions Inc.	28,816	-	(4,210)	24,606	-	25,000	-	-	(394)	24,606
BioSyent Inc.	17,817	-	(2,757)	15,060	7,185	9,056	-	-	(1,180)	15,060
Avante Logixx Inc.	-	3,500	680	4,180	-	3,500	-	-	680	4,180
Other	5,686	2,050	2,933	10,669	3,069	7,636	3,881	1,965	1,881	10,669
Private company investments										
Carson, Dunlop & Associates Ltd. (i)	11,552	-	1,848	13,400	-	12,884	-	-	516	13,400
Total investments	153,560	6,810	(8,687)	151,682	98,826	62,925	31,581	15,503	6,009	151,682

(i) The Company's investment in Carson, Dunlop & Associates Ltd. is held in its majority owned subsidiary 2794677 Ontario Corp.

UPDATE ON INVESTMENT POSITIONS

PUBLIC COMPANY INVESTMENTS

Information Services Corporation

Business Overview

Information Services Corporation ("ISC") is a leading provider of registry and information management services and technology for public data and records. The company is headquartered in Saskatchewan, Canada. ISC was formed as a Saskatchewan-based crown corporation in January 2000 and was privatized through an initial public offering in May 2013, when the provincial government sold 69% of the company to public shareholders. ISC is listed on the TSX under the symbol "ISV".

ISC operates the following three reportable segments:

Registry Operations: ISC's Registry Operations delivers registry and information services on behalf of governments and private sector organizations. Most significantly, ISC operates the province of Saskatchewan's land, property, and corporate registry under an exclusive 20-year Master Service Agreement, expiring in 2033. Revenue is earned through fees charged to governments and private sector organizations for accessing registration, search, maintenance, and other ancillary services.

Services: ISC's Services segment delivers solutions uniting public records data, customer authentication, corporate services, collateral management and asset recovery to support registration, due diligence and lending practices of clients across Canada. ISC's offerings are generally categorized into three divisions, namely Corporate Solutions, Regulatory Solutions, and Recovery Solutions.

Technology Solutions: ISC provides the development, delivery, and support of registries technology solutions. Revenue is generated through the sale of software licenses related to the technology platform, the provision of technology solution definition and implementation services and the provision of monthly hosting, support and maintenance services.

Additional information about the company, including the impacts of the COVID-19 pandemic on its business performance, can be found on ISC's website at www.isc.ca.

Transaction Description

The Company's Investment Committee approved the investment in ISC in January 2020 and the Company began accumulating its targeted position shortly thereafter. At September 30, 2021, the Company owned 1,074,967 common shares of ISC, representing a 6.1% equity ownership interest in the company. The fair value of the Company's investment in ISC at September 30, 2021 was \$29.7 million, resulting in an unrealized gain of \$13.4 million.

Hamilton Thorne Ltd.

Business Overview

Hamilton Thorne Ltd. ("Hamilton Thorne") is a global provider of laboratory instruments, consumables, software and services to the assisted reproductive technology ("ART"), research, and cell biology markets. The company develops, manufactures and markets products and delivers services that are sold under its own brand names, as well as provides an array of third-party equipment and consumables to meet customer requirements, ranging from accessories to support its core products to the full complement of equipment to outfit a new laboratory. Hamilton Thorne is listed on the TSX Venture Exchange (the "TSXV") under the trading symbol "HTL".

Hamilton Thorne's proprietary instrument, equipment and software product lines include precision laser devices, imaging systems, incubators, laminar flow workstations, air purification systems, control rate freezers, lab monitoring systems and micromanipulation systems. Its laser products attach to standard inverted microscopes and operate as micro-surgical devices, enabling a wide array of scientific applications and In Vitro Fertilization ("IVF") procedures. Hamilton Thorne's image analysis systems are designed to bring quality, efficiency and reliability to studies of reproductive cells in the human fertility, animal sciences, and reproductive toxicology fields. The company's incubators and workstations improve outcomes through controlling temperature, air flow, humidity, and air quality. Its air filtration products improve air quality in the laboratory. Hamilton Thorne's micromanipulation system is targeted to assist the embryologist in performing critical procedures in the IVF lab with a high level of precision and reliability.

Hamilton Thorne's proprietary consumables and services cover a wide range of customer needs. Its GM501 family of products provides the IVF lab with a comprehensive cell culture media solution, including oocyte handling, sperm processing, embryo culture, and cryopreservation. Its line of glass micropipettes complements its micromanipulator system. The company's quality control assays are used in IVF labs for testing equipment and materials' toxicity to ensure the safest environment for successful embryo development. Its services cover a broad range of user needs, ranging from equipment service contract and maintenance programs; quality control testing services to manufacturers of medical devices, culture media and consumables used in IVF labs; and laboratory design and installation services.

The third-party products that Hamilton Thorne distributes cover a wide range of specialized equipment, software, accessories and consumables utilized by its IVF clinic, animal breeding, research, and cell biology customers, including microscopes, workstations, vitrification products, dishes and slides.

Hamilton Thorne sells its products and services through a growing direct sales force based in the US, Germany, France, the UK, Denmark, and Australia, and through distributors, to well over 1,000 fertility clinics, hospitals, pharmaceutical companies, biotechnology companies, educational institutions and other commercial and academic research establishments in over 75 countries.

The clinical products that Hamilton Thorne markets are generally cleared for sale in the US, Europe (and other territories accepting a CE Mark), China, and Canada as well as a number of other markets.

In order to increase the size and scale of its business, broaden its offerings of products and services, and positively affect its quality of revenue, Hamilton Thorne have augmented organic growth and R&D initiatives through the strategic acquisition of both operating companies and established product lines. From 2015 to 2019, Hamilton Thorne completed five acquisitions. These acquisitions have expanded and diversified the range of proprietary products in its portfolio, significantly increased its service and consumables revenues, and added direct sales territories.

In April 2021 Hamilton Thorne acquired Tek-Event Pty. Ltd., the manufacturer of the Cell-Tek Microscope Chamber, a specialized workstation that is used in ART and laboratory markets worldwide with direct sales operations in Australia. In July 2021 Hamilton Thorne acquired IVFtech ApS, which manufactures laminar flow workstations for controlling temperature, air flow, and air quality in ART and laboratory markets worldwide, as well as flatbed incubators and a number of accessory and related products. The company also acquired IVFtech's affiliated direct sales business, K4 Technology ApS. These most recent acquisitions add a number of high-quality product lines with significant growth potential to its product portfolio and establish a direct sales presence for the entire Hamilton Thorne product range in Australia and the Nordics region of Denmark, Sweden, Norway, Finland and Iceland.

Hamilton Thorne is headquartered in Beverly, Massachusetts. The company has production, sales and/or laboratory facilities in the US, Germany, England, Denmark, and Australia and sales/support personnel in France, Singapore, and Malaysia. The company's operations are conducted by its wholly owned subsidiaries, Hamilton Thorne, Inc. and Embryotech Laboratories Inc., each a Delaware corporation, Gynemed & Co. GmbH KG, a German Limited Partnership, Planer Limited, a UK limited company, Tek-Event Pty. Ltd, an Australian limited company, and IVFtech ApS and K4 Technology ApS, each a Danish company.

Additional information about the company, including the impacts of the COVID-19 pandemic on its business performance, can be found on Hamilton Thorne's website at www.hamiltonthorne.com.

On January 19, 2021, Marc Robinson, the Company's Managing Director, Investments, was appointed to the board of directors of Hamilton Thorne.

Transaction Description

The Company's Investment Committee approved the investment in Hamilton Thorne in February 2020 and the Company began accumulating its targeted position shortly thereafter. At September 30, 2021, the Company owned 17,495,500 common shares in Hamilton Thorne, representing a 12.4% equity ownership interest in the company. The fair value of the Company's investment in Hamilton Thorne at September 30, 2021 was \$31.7 million, resulting in an unrealized gain of \$10.1 million.

Points International Ltd.

Business Overview

Points International Ltd. (“Points”) is a global leader in providing technology solutions to the loyalty industry on one unified operating platform. Points operates a portfolio of white-labelled services that facilitate the accrual or redemption of loyalty program currency (points or miles) for loyalty programs worldwide. Accrual transactions are typically focused on generating revenue for our loyalty program partners while redemption transactions are focused on offering additional engagement options for program members that are cost effective for the loyalty program.

All of the company’s services are operated off a single unified operating platform called the Loyalty Commerce Platform (“LCP”). The LCP provides broad access to loyalty transaction capabilities, program integration, offers and automated marketing, reporting and analytics, enterprise-grade security, and real-time fraud services. Points has direct, real-time integrations into its partners’ loyalty program databases that allow for member validation, information sharing, as well as the debit and/or credit of miles/points.

Points is a trusted partner to the world’s leading loyalty programs, with approximately 60 commercial agreements or integrations with loyalty programs globally, including Southwest Airlines’ Rapid Rewards, Marriott Bonvoy, Chase Ultimate Rewards, and the Emirates Skywards program. Most of its commercial contracts enable it to transact directly or indirectly with the loyalty programs’ member base to facilitate the sale, redemption or earning of loyalty currency online. Over 95% of Points revenue is transaction based, which consists of a margin, commission or transaction fee that it earns on the loyalty currency and transactions it processes.

The company is headquartered in Toronto and maintains offices in San Francisco, United States, London, England, Singapore and Dubai. The company’s shares are listed on both the TSX under the trading symbol “PTS” and on the NASDAQ Capital Market under the trading symbol “PCOM”.

Additional information about the company, including the impacts of the COVID-19 pandemic on its business performance, can be found on Points’ website at www.points.com.

Transaction Description

The Company’s Investment Committee approved the investment in Points in February 2020 and the Company began accumulating its targeted position shortly thereafter. At September 30, 2021, the Company owned 1,032,155 common shares of Points, representing a 6.9% equity ownership interest in the company. The fair value of the Company’s investment in Points at September 30, 2021 was \$22.4 million, resulting in an unrealized gain of \$2.3 million.

Qusitive Technology Solutions Inc.

Business Overview

Qusitive Technology Solutions Inc. (“Qusitive”) was established as a strategic Microsoft National Solution Provider in the U.S. and has grown its position to a premier global Microsoft partner that harnesses Microsoft cloud platforms and complementary technologies, including custom solutions and first-party offerings, to generate transformational impact for enterprise customers. Qusitive has two operating segments, Cloud Solutions and Payment Solutions. The company’s shares are listed on the TSXV under the trading symbol “QUIS”.

Qusitive’s Cloud Solutions segment is a full-service digital technology consulting firm whose mission is to acquire and integrate companies to become the leading provider of Microsoft professional services in North America. The

company is a premier, global Microsoft partner that harnesses the Microsoft platform and complementary technologies, including custom solutions and first-party offerings, to generate meaningful impact for enterprise customers. On April 1, 2021, Qusitive announced the closing of the agreement to acquire Microsoft Healthcare Cloud Solutions expert Mazik Global.

Qusitive's Payment Solutions segment is comprised of two key business units: merchant services and payment processing. The payment processing business unit is comprised of the LedgerPay platform which is an innovative cloud-based payment processing and payments intelligence and data insights solution designed to optimize a merchant's payment processing and consumer engagement operations. LedgerPay is a scalable service and the only payment processing platform solution leveraging the Microsoft Azure cloud to deliver a full suite of acquiring, issuing, and processing services with unmatched speed, security, and access to customer's data. Qusitive's payments solutions segment provides payment processing services to both merchants and independent sales organizations (ISOs). The company's flagship product platform, LedgerPay, is a cloud-based data insights and payments intelligence suite that turns everyday transaction data into customer loyalty for merchants. On May 7, 2021, Qusitive acquired Bankcard USA Merchant Services, Inc ("Bankcard"), which brought an established all-in-one merchant payment services provider to the merchant services segment with over US\$3.0 billion of payment volume. BankCard has a seasoned payments industry management team, strong in-house sales team, deep risk management program and attractive recurring revenue model with card-not present volume representing approximately 70%. The acquisition of BankCard is expected to serve as a growth catalyst for Qusitive's LedgerPay payment processing with a focused strategy on migrating BankCard merchants to LedgerPay Payment Processing.

Additional information about the company, including the impacts of the COVID-19 pandemic on its business performance, can be found on Qusitive's website at www.qusitive.com.

Transaction Description

The Company's Investment Committee approved the investment in Qusitive on March 3, 2021. On March 8, 2021, the Company entered into a binding agreement with Qusitive to purchase, on a non-brokered private placement basis, 16,000,000 common shares of Qusitive from treasury at a price of \$1.25 per common share for an aggregate subscription amount of \$20,000,000.

In conjunction with closing the private placement, the Company entered into an Investor Rights Agreement, which provided, among other things, a right for the Company to nominate one member to the board of directors of Qusitive, a pre-emptive right to participate in future offerings of securities of the company and requires the Company not to sell the common shares acquired through the private placement for 12 months following the closing of the private placement. In connection with the private placement, the Company received a capital commitment fee payment from Qusitive equal to 3.5% of the aggregate subscription amount. Both the Investor Rights Agreement and Registration Rights Agreement are available under Qusitive's profile on www.sedar.com.

On April 8, 2021, the Company completed the purchase of 3,333,333 subscription receipts of Qusitive on a private placement basis for consideration of \$5.0 million. On May 7, 2021, the subscription receipts were converted to 3,333,333 common shares of Qusitive. In connection with this private placement, the Company received a capital commitment fee payment from Qusitive equal to 3.5% of the aggregate subscription amount.

On June 28, 2021, Qusitive announced that Laurie Goldberg, the Company's nominee under the Investor Rights Agreement, was elected to its board of directors.

At September 30, 2021, the Company owned 19,333,333 common shares of Qusitive, representing a 6.0% equity ownership interest in the company. The fair value of the Company's investment in Qusitive at September 30, 2021 was \$24.6 million, resulting in an unrealized loss of \$0.4 million.

BioSyent Inc.

Business Overview

BioSyent Inc. (“BioSyent”) is a publicly traded specialty pharmaceutical company which, through its wholly owned subsidiaries, BioSyent Pharma Inc. and BioSyent Pharma International Inc., sources, acquires or in-licences and further develops pharmaceutical and other healthcare products for sale in Canada and certain international markets. The head office of BioSyent is in Mississauga, Ontario. BioSyent is listed on the TSX under the symbol “RX”.

BioSyent’s vision is to be the leading independent Canadian provider of innovative healthcare products. BioSyent is focused on innovative products that are sourced through international partnerships. These products are unique due to manufacturing complexities, novel technologies, therapeutic advantages and/or strong, defensible intellectual property rights. The company’s strategy allows it to commercialize these products as brands acquired or licensed to it by partners. The company intends for its products to be differentiated and to improve patient lives. BioSyent works with, and supports, healthcare practitioners in achieving this objective.

BioSyent has developed sourcing arrangements with partners from around the world. The company has a flexible format for such arrangements. The company seeks long-term buy-sell agreements or in-licensing arrangements with or without royalties or payments linked to milestone events such as regulatory approvals or reimbursement by formularies. BioSyent exercises diligence when sourcing new products. Some of the steps in this process involve reviewing market data and market trends, interviewing key healthcare practitioners or medical advisory boards and obtaining opinions on reimbursement possibilities with payers. Once the company has decided to proceed with a new product opportunity, it acquires or licenses exclusive Canadian and/or international market rights to that product. After the acquisition or in-licensing of the product, the company manages the product through the regulatory and product registration process and, once approved, commercializes the product in Canada and/or international markets.

Additional information about the company, including the impacts of the COVID-19 pandemic on its business performance, can be found on BioSyent’s website at www.biosyent.com.

Transaction Description

The Company’s Investment Committee approved the investment in BioSyent in July 2020. At September 30, 2021, the Company owned 2,121,100 common shares of BioSyent, representing a 16.5% equity ownership interest in the company. The fair value of the Company’s investment in BioSyent at September 30, 2021 was \$15.1 million, resulting in an unrealized loss of \$0.3 million.

Avante Logixx Inc.

Business Overview

Avante Logixx Inc. (“Avante”) is a leading provider of technology enabled security solutions to both commercial and residential customers. Avante is an Ontario corporation listed on the TSXV under the trading symbol “XX”.

Avante is organized into two operating segments consisting of Logixx Security Inc. (“Logixx Security”) and Avante Security Inc. (“Avante Security”), based on the type of customer. Logixx Security focuses on providing enterprise customers with protective services, electronic security and monitoring and managed services across Canada. Avante Security focuses on providing residential customers with similar services within central Toronto and Muskoka, Ontario.

The company's strategy focuses on acquiring, managing and building a diversified portfolio of industry leading businesses providing specialized, mission-critical solutions that address the security risks of its customers. Avante's businesses continuously develop innovative solutions that enable its customers to achieve their security and risk objectives.

On August 25, 2021, Avante announced that its board of directors will oversee a strategic review process (the "Strategic Review") to consider and evaluate various strategic alternatives available to the company in the pursuit of maximizing shareholder value. The Strategic Review will explore, review and evaluate a broad range of alternatives available to the company, with a focus on unlocking shareholder value, which could include, but are not limited to, further acquisitions, a sale of one or more divisions, a business combination, a merger or reverse merger with another party or parties, introduction of a new significant strategic shareholder and other alternatives for potentially enhancing shareholder value. The Strategic Review will also evaluate the company continuing as currently operating under its articulated organic and strategic plans as a public company.

Additional information about the company, including the impacts of the COVID-19 pandemic on its business performance, can be found on Avante's website at www.avantelogixx.com.

Transaction Description

The Company's Investment Committee approved the investment in Avante in July 2021. At September 30, 2021, the Company owned 2,000,000 common shares of Avante, representing a 9.4% equity ownership interest in the company. The fair value of the Company's investment in Avante at September 30, 2021 was \$4.2 million, resulting in an unrealized gain of \$0.7 million.

Other Investments

Other investments represent a position in a Canadian public company that the Company is in the process of accumulating its targeted position. The Company will provide further information on this investment once it has materially completed accumulating its targeted position.

PUBLIC COMPANY INVESTMENTS MONETIZED DURING THE PERIOD

During the nine month period ended September 30, 2021, the Company monetized two of its public company investments, resulting in the recognition of a realized gain on these investments of \$15.5 million.

The Company's investment in People Corporation ("People Corp.") was monetized in February 2021. People Corp. is in the business of delivering employee benefits consulting, third party benefits administration, pension consulting, human resources consulting and executive search and staff recruitment services. The Company's initial investment in People Corp. was made in April 2020. At that time, People Corp. was publicly-traded on the TSXV under the symbol "PEO".

On December 14, 2020, People Corp. announced that it had entered into a plan of arrangement (the "Arrangement"), pursuant to which an entity controlled by certain investment funds managed by the Merchant Banking business of Goldman Sachs & Co. LLC, acquired all of the outstanding common shares of People Corp. for \$15.22 in cash per share. The purchase price represented a 37% premium to the 20-day volume-weighted average price per share for the period ended December 11, 2020, and a 36% premium to the closing price of December 11, 2020. The Arrangement was approved by People Corp.'s shareholders at a special meeting held on February 11, 2021 and People Corp. obtained a final order from the Ontario Superior Court of Justice (Commercial List) in respect of the Arrangement on February 12, 2021. People Corp. was delisted from the TSXV at the close of trading on February 18,

2021. As a result of the Arrangement, in the nine month period ended September 30, 2021, the Company recognized a realized gain of \$13.5 million on its investment of \$14.2 million.

In February 2021, the Company's Investment Committee approved the divestiture of an investment in a Canadian public company in which the Company had yet to accumulate its targeted position as the share price of this company had increased to a level that the Company was no longer interested in adding to its position. In the nine month period ended September 30, 2021, the Company recognized a realized gain of \$2.0 million on its investment of \$1.9 million in this company.

PRIVATE COMPANY INVESTMENTS

Carson, Dunlop & Associates Ltd.

Business Overview

Carson, Dunlop & Associates Ltd. ("Carson Dunlop") is a leading provider of proprietary technology-enabled education services and software for home inspectors across Canada and the United States, as well as a leading provider of home inspections services in the Greater Toronto Area. Carson Dunlop's direct to consumer online education business through their private career college is the market share leader in Canada with a growing presence in the United States, and its curriculum is also utilized by third-party colleges and associations. Its home inspection software tools and mobile app, provided on a credit and subscription basis, are used to generate home inspections in over 220,000 homes annually across the United States and Canada. The company was founded in 1978 and is headquartered in Toronto.

Alan Carson, the co-founder of Carson Dunlop and owner, remains the Chief Executive Officer of Carson Dunlop and a significant shareholder of Carson Dunlop, with an approximate 22% ownership.

On March 23, 2021, Graham Badun was appointed as Chief Executive Officer of 2794677 Ontario Corp. and President of Carson Dunlop. 2794677 Ontario Corp. is a new platform company controlled by the Company, which holds Carson Dunlop as its foundational asset, focused on organic growth initiatives and acquisitions of complementary businesses within property technology, education technology and home services. Mr. Badun also serves as a director of both companies.

Additional information about Carson Dunlop can be found on its website at www.carsondunlop.com.

Transaction Description

On March 23, 2021, the Company, through its subsidiary 2794677 Ontario Corp., completed the acquisition of an approximate 78% controlling interest in Carson Dunlop. The Company invested \$11,750,000, plus a working capital adjustment of \$1,633,819, for approximately 78% of Carson Dunlop, representing a total enterprise value of \$15 million. To fund the acquisition, 2794677 Ontario Corp. issued 12,883,819 new Class A common shares to the Company for proceeds of \$12,883,819 and the Company provided 2794677 Ontario Corp. with an inter-company loan of \$500,000. On June 28, 2021, 2794677 Ontario Corp. issued to the Chief Executive Officer of 2794677 Ontario Corp. and his spouse collectively 555,556 non-voting Class B common shares for proceeds of \$500,000. This resulted in the Company's ownership interest in 2794677 Ontario Corp. decreasing from 100% to 95.9%. In July 2021, these funds were used by 2794677 Ontario Corp. to repay the \$500,000 inter-company loan to the Company.

At September 30, 2021, the Company estimated the fair value of its investment in Carson Dunlop using a discounted cash flow analysis for Carson Dunlop's three business units based on multi-year free cash flow forecasts with an assumed after-tax discount of 25.0% and a 8.8x earnings before interest, taxes, depreciation and amortization exit

multiple. The free cash flow forecasts used in the valuation were based on estimates derived from financial information for Carson Dunlop's three business units prepared in the third quarter of 2021 by the Company's management.

At September 30, 2021, the fair value of the Company's investment in Carson Dunlop was increased to \$13,400,000, comprised of its investment of \$12,883,819 and a positive market adjustment of \$516,181. The increase in fair value was driven by an improved outlook on the business. The valuation also considered the payment of a \$1,700,000 dividend by Carson Dunlop in April 2021, of which \$1,331,667 was paid to the Company.

SELECT ANNUAL INFORMATION

Table 3: Statement of Financial Position Highlights


(\$ thousands)	Sep. 30 2021	Dec. 31 2020
Cash and cash equivalents	78,261.3	109,800.3
Investments, at fair value	151,682.5	98,826.0
Other assets	697.3	1,486.2
Total assets	230,641.1	210,112.5
Accounts payable and accrued liabilities	4,054.4	2,893.8
Income taxes payable	256.5	250.7
Deferred income tax liability	2,055.9	48.6
Total liabilities	6,366.8	3,193.1
Shareholders' equity	224,274.3	206,919.4
Total liabilities and shareholders' equity	230,641.1	210,112.5
Book value per share	\$ 5.26	\$ 4.83

Table 4: Statement of Comprehensive Income Highlights

(\$ thousands)	Nine months ended Sep. 30, 2021	Nine months ended Sep. 30, 2020
Realized gain on sale of investments	15,502.9	-
Net change in unrealized gain on investments	6,009.4	7,498.2
Interest	637.1	1,581.2
Dividends	2,000.8	442.0
Other income	884.0	-
Total revenue	25,034.2	9,521.4
Total expenses	4,991.8	3,233.0
Income before income taxes	20,042.4	6,288.4
Provision for income taxes	2,007.2	-
Net income and comprehensive income	18,035.2	6,288.4
Earnings per share		
Basic	\$ 0.42	\$ 0.15
Diluted	\$ 0.42	\$ 0.15

RESULTS OF OPERATIONS**Book Value per Share**

The Company's book value per share at September 30, 2021 was \$5.26, an increase of 8.9% or \$0.43 per share since December 31, 2020. The increase in the book value per share is primarily attributed to the Company recording realized and unrealized gains on its investments of \$21.5 million in the period. The following graph shows the Company's book value per share since November 21, 2019, the date the Company closed the Offerings.



Nine Months Ended September 30, 2021

In the nine months ended September 30, 2021, the Company deployed \$62.9 million into its public and private company investment portfolio and as at September 30, 2021 had cash resources of approximately \$78 million available to be invested.

The Company had revenue of \$25.0 million for the nine months ended September 30, 2021, compared to revenue of \$9.5 million for the comparative period last year. The current period's revenue consisted of the following:

- a realized gain on sale of investments of \$15.5 million, largely attributed to the \$13.5 million realized gain recorded on the Company's sale of its investment in People Corp.;
- a net change in unrealized gain of investments of \$6.0 million;
- interest income of \$637.1 thousand;
- dividend income of \$2.0 million, of which \$1.33 million was from its investment in Carson Dunlop and \$645.0 thousand was from its investment in ISC; and
- other income of \$884.0 thousand. Other income includes the 3.5% capital commitment fees earned on the Company's investments in Quisitive.

In the comparative period last year, the Company's revenue consisted of a net change in unrealized gain of investments of \$7.5 million, interest income of \$1.6 million and dividend income of \$442.0.

For the nine months ended September 30, 2021, the Company incurred expenses of \$5.0 million, as compared to \$3.2 million in 2020. The increase in total expenses is mainly attributed to the higher amount of share-based compensation recorded in the current period. The expenses in the nine month period include the following: compensation expenses of \$1.7 million; share-based compensation expenses of \$2.4 million; office, general and administrative expenses of \$633.6 thousand; professional fees (comprised of legal and audit fees) of \$360.0 thousand; director fees of \$158.0 thousand; brokerage fees and expenses of \$94.3 thousand; and reimbursement of expenses of (\$357.7) thousand.

For the nine months ended September 30, 2021, the Company recorded a provision for income taxes of \$2.0 million as compared to a \$nil provision for income tax expense in the comparative period last year.

Net income for the nine months ended September 30, 2021 was \$18.0 million or \$0.42 per share, compared to net income of \$6.3 million or \$0.15 per share for the nine months ended September 30, 2020.

SUMMARY OF QUARTERLY RESULTS

The following table sets out selected quarterly results of the Company for the eight quarters prior to the effective date of this report. The information contained herein is drawn from the interim financial statements of the Company for each of the aforementioned eight quarters. The weighted average number of outstanding common shares used in the earnings per share calculations for all periods presented reflect the 5:1 share consolidation of the Company's issued and outstanding multiple voting shares and subordinate voting shares which became effective on November 20, 2019. The multiple voting shares and the subordinate voting shares are both classes of common shares of the Company.

Table 5: Summary of Quarterly Results**Table 5: Summary of Quarterly Results**

	2021 Sep 30	2021 Jun 30	2021 Mar 31	2020 Dec 31	2020 Sep 30	2020 Jun 30	2020 Mar 31	2019 Dec 31
(\$ thousands)								
Realized gain on sale of investments	-	-	15,502.9	-	-	-	-	-
Net change in unrealized gain (loss) on investments	(8,687.0)	15,582.2	(885.9)	15,825.3	10,972.2	5,604.1	(9,078.1)	-
Interest	166.8	198.8	271.6	307.6	323.5	338.8	918.8	484.7
Dividends	239.2	1,546.7	215.0	211.8	197.8	191.6	52.7	-
Other income	-	184.0	700.0	-	-	-	-	-
Total revenue	(8,281.0)	17,511.7	15,803.6	16,344.7	11,493.5	6,134.5	(8,106.6)	484.7
Total expenses	1,682.5	1,681.8	1,627.6	1,728.5	1,152.6	1,003.4	1,077.0	1,109.5
Income (loss) before income taxes	(9,963.5)	15,829.9	14,176.0	14,616.2	10,340.9	5,131.1	(624.8)	(608.0)
Provision for (recovery of) income taxes	(1,521.0)	1,743.2	1,785.1	1,583.0	-	-	-	-
Net income (loss) and comprehensive income (loss)	(8,442.5)	14,086.8	12,390.9	13,033.2	10,340.9	5,131.1	(624.8)	(608.0)
(\$)								
Earnings (loss) per common share								
Basic	(0.20)	0.33	0.29	0.30	0.24	0.12	(0.21)	(0.03)
Diluted	(0.19)	0.32	0.29	0.30	0.24	0.12	(0.21)	(0.03)

QUARTERLY TREND ANALYSIS

The decrease in the Company's revenue in the quarter ended September 30, 2021 is attributed to the unrealized loss on investments. The increase in the Company's revenue in the quarters ended June 30, 2021, March 31, 2021, December 31, 2020, September 30, 2020 and June 30, 2020 is attributed to the realized and unrealized gain on investments recorded on the Company's investments. The decrease in the Company's revenue in the quarter ended March 31, 2020 is attributed to the unrealized loss on investments resulting from a decrease in the fair value of the Company's public company investments due primarily to the initial significant market impact of COVID-19. The Company's only source of revenue in quarters prior to March 31, 2020 was interest revenue.

The Company's quarterly expenses have been relatively consistent for the last four quarters. The Company's expenses include the costs to fully support its operations as an investment holding company, including compensation expenses, share based compensation expenses, professional fees, and brokerage fees and commissions directly tied to the Company's investing activity.

In the quarters ended September 30, 2021, June 30, 2021, March 31, 2021 and December 31, 2020, the Company recorded a provision for income taxes of (\$1.5) million, \$1.7 million, \$1.8 million and \$1.6 million, respectively.

THIRD QUARTER ENDED SEPTEMBER 30, 2021

Net loss before income taxes for the quarter ended September 30, 2021 was \$10.0 million, compared to a net income before income taxes in the quarter ended September 30, 2020 of \$10.3 million. Revenue in the quarter ended September 30, 2021 included a net change in unrealized loss on its investments of \$8.7 million, interest income of \$166.8 thousand and dividend income of \$229.2 thousand. In the comparative quarter last year, the Company's revenue included an unrealized gain on its investments of \$11.0 million, interest income of \$323.5 thousand and dividend income of \$197.8 thousand. Net loss for the quarter ended September 30, 2021 was \$8.4 million or (\$0.20) per share, compared to net income of \$10.3 million or \$0.24 per share for the quarter ended September 30, 2020.

LIQUIDITY AND CAPITAL RESOURCES

The Company had a cash balance of \$78.3 million at September 30, 2021, representing 33.9% of total assets, compared with \$109.8 million at December 31, 2020. The \$31.5 million decrease in the Company's cash balance at September 30, 2021 compared to December 31, 2020 is primarily attributed to the Company's investing activities. During the nine month period ended September 30, 2021, the Company invested \$62.9 million offset by proceeds of \$31.6 million from sale of two of its public company investments. The Company's current liabilities increased to \$4.3 million at September 30, 2021, representing 1.9% of total assets, from \$3.1 million at December 31, 2020. The Company is well capitalized with adequate financial resources to continue its long-term investment strategy.

The Company's equity was \$224.3 million as at September 30, 2021, compared to \$206.9 million as at December 31, 2020. The increase in the Company's equity balance at September 30, 2021 compared to December 31, 2020 is primarily attributed to the Company recording realized and unrealized gains on its investments of \$21.5 million in the nine month period ended September 30, 2021.

The Company's capital is primarily utilized in its ongoing business operations to execute on its public company and private company investment strategies. Other than the potential impact of COVID-19, as discussed herein, the Company is not aware of any trends, demands, commitments, events, or uncertainties that may result in the Company's liquidity or capital resources either materially increasing or decreasing at present or in the foreseeable future. Material increases or decreases in the Company's liquidity and capital resources will be substantially determined by the success or failure of its operation as an investment holding company.

NORMAL COURSE ISSUER BID

The Company's current Normal Course Issuer Bid (the "NCIB") commenced on June 8, 2021 and is effective until the earlier of June 7, 2022 and the date on which the Company has purchased the maximum number of subordinate voting shares permitted under the NCIB. Pursuant to the NCIB, the Company may purchase up to 1,488,480 of its subordinate voting shares, representing 10% of the public float. The price that the Company will pay for any such subordinate voting shares will be the market price of such shares on the TSX, or such alternative Canadian trading systems, at the time of acquisition. All subordinate voting shares acquired under the NCIB are cancelled.

In connection with its NCIB, the Company has entered into an Automatic Securities Repurchase Plan which provides standard instructions regarding how the Company's subordinate voting shares are to be purchased under the NCIB during certain pre-determined trading blackout periods, subject to pre-established parameters. Outside of these pre-determined trading blackout periods, purchases under the Company's NCIB are completed based upon management's discretion and in accordance with the TSX rules.

In the nine month period ended September 30, 2021, there were 181,122 subordinate voting shares (2020 - 55,328) purchased at a cost of \$746.3 thousand (2020 - \$180.7 thousand) under the Company's current NCIB and previous NCIB, which expired on June 7, 2021. The discount paid to purchase the shares below the stated value was allocated to Retained earnings.

TRANSACTIONS WITH RELATED PARTIES

All transactions with related parties have occurred in the normal course of operations, as follows:

- The Company and Federated Capital Corp. ("Federated Capital"), the parent company of Fax Investments, entered into an agreement (the "Administrative Services Agreement") on November 21, 2019 whereby the Company is provided access to certain office space and supplies, computers, communication equipment and administrative personnel provided by Federated Capital. As consideration for such services (including

the use of office space), the Company has agreed to pay Federated Capital a fee equal to the costs and expenses of Federated Capital in providing such services and office space, plus 5%. For the nine month period ended September 30, 2021, Federated Capital charged the Company expenses under the Administrative Services Agreement of \$129.8 thousand (2020 - \$103.0 thousand). On May 26, 2021, the Company granted the Chief Executive Officer (“CEO”) \$300.0 thousand of Restricted Share Units (“RSUs”) in lieu of the Company paying the CEO short-term cash compensation. Prior to this, Federated Capital paid all compensation related expenses of the CEO and did not allocate these costs to the Company. In addition, Federated Capital pays the compensation related expenses of an Executive Vice-President of the Company and does not allocate these costs to the Company.

- Fax Investments has agreed to pay at the end of each fiscal year of the Company, certain specified operating expenses of the Company exceeding 2.85% of the Company’s average month-end book value for such fiscal year until December 31, 2024. The Company’s specified operating expenses were above this threshold in the nine month period ended September 30, 2021. Accordingly, the Company has recorded a receivable of \$357.7 thousand from Fax Investments for the reimbursement of excess operating expenses in the nine month period ended September 30, 2021 (2020 - \$nil).
- On March 23, 2021, the Company’s subsidiary, 2794677 Ontario Corp., completed the acquisition of an approximate 78% controlling interest in Carson Dunlop for cash consideration of \$11.8 million, plus a working capital adjustment of \$1.6 million. The acquisition was funded by the Company acquiring Class A common shares of 2794677 Ontario Corp. for \$12.9 million and providing an intercompany loan of \$500.0 thousand. The intercompany loan was repaid by 2794677 Ontario Corp. in July 2021.

Carson Dunlop agreed to reimburse the Company for its third-party transaction and due diligence expenses incurred in this transaction. As a result of this commitment, during the period ended September 30, 2021, Carson Dunlop reimbursed the Company \$343.6 thousand of the third-party transaction and due diligence expenses.

Key Management Personnel

Key management personnel are defined as those individuals having authority and responsibility for planning, directing, and controlling the activities of the Company. The Company considers its executive officers and its directors to be its key management personnel. Prior to the grant of the RSUs to the CEO on May 26, 2021 (refer to Transactions with Related Parties), Federated Capital paid the CEO’s annual base salary of \$200,000 and did not allocate this cost to the Company. In addition, Federated Capital pays an Executive Vice-President’s annual base salary of \$100,000 and does not allocate this cost to the Company.

Compensation related expenses for key management personnel for the nine month period ended September 30, 2021 was \$1.1 million (2020 - \$480.9 thousand).

These expenditures were allocated as follows in the financial statements:

Table 6: Key Management Personnel

(\$ thousands)	Sep. 30 2021	Sep. 30 2020
Compensation (Refer to Transactions with Related Parties)	\$ 256.4	\$ 235.9
Director fees	157.5	173.3
Share-based compensation	730.1	71.7
	\$ 1,144.0	\$ 480.9

RISKS AND UNCERTAINTIES

In addition to the information contained in this MD&A, and the risk factors discussed in the Company's most recent Annual Information Form dated March 25, 2021 filed with the securities regulatory authorities in Canada, available at www.sedar.com, investors or security holders should carefully consider other risk factors which may have a material adverse effect on the business, financial condition or results of operations of the Company.

CRITICAL ACCOUNTING ESTIMATES

Preparation of financial statements in conformity with IFRS requires management to make judgments, estimates and assumptions that affect the application of accounting policies, the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities, and the reported amounts of revenues and expenses during the period. Estimates and assumptions are continuously evaluated and are based on management's experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances. Uncertainty about these judgments, estimates, and assumptions could result in outcomes that could require a material adjustment to the carrying amount of the asset or liability affected in future periods.

Information about significant areas of estimation uncertainty considered by management in preparing the financial statements are as follows:

Fair Value Measurement of Private Company Investment

The Company holds an investment in a private company which is not quoted in active markets and for which there may or may not be recent comparable transactions. In determining the fair value of this investment, the Company has made significant accounting judgments and estimates. See Notes 2 and 4 of the Condensed Interim Financial Statements for more information on the fair value measurement technique and types of unobservable inputs employed by the Company in its valuation of its private company investment.

Amount of Accrued Liabilities

Accrued liabilities are recorded based on an estimate of unbilled work performed by the Company's vendors as well as any other payments which the Company will be required to make in relation to the current year's operations. Management makes these estimates based on historical billings and its knowledge of current operations. These estimates will affect the reported amounts of accrued liabilities and expenses.

Income Taxes

Income taxes relating to uncertain tax positions are recognized based on the expected value of the tax settlement with the related tax authority. Judgment is required to determine the amount of tax provision relating to these uncertain tax positions.

Deferred Tax Assets

Deferred tax assets are recognized in respect of tax losses and other temporary differences to the extent that it is probable that taxable profit will be available against which the losses can be utilized. Judgment is required to determine the amount of deferred tax assets that can be recognized, based upon the likely timing and level of future taxable profits, together with future tax planning strategies.

Founder Warrants

The Company uses the Black-Scholes model to calculate the value of Founder Warrants issued as part of the Offering. The Black-Scholes model requires six key inputs to determine a value for a warrant: risk-free interest rate, exercise price, market price at rate of issuance, expected yield, expected life and expected volatility. Certain of the inputs are estimates, which involve considerable judgment and are or could be affected by significant factors that are out of the Company's control. Proceeds from the Offering, net of issuance costs, were allocated between subordinate voting shares and Founder Warrants issued according to their relative fair value.

Investment Entity

Management has applied judgment in determining whether the Company meets the criteria required under IFRS 10, to be classified as an investment entity.

FINANCIAL RISK MANAGEMENT

Credit Risk

Credit risk is the risk of loss associated with a counter-party's inability to fulfil its payment obligations. The Company's maximum exposure to credit risk was \$638.7 thousand as of September 30, 2021 (September 30, 2020 - \$784.2 thousand), being the value of its dividend receivable, interest receivable and receivables from related parties. Management believes these receivables are a low credit risk. As of September 30, 2020, the Company's exposure to credit risk consisted of its interest receivable and dividend receivable. There have been no changes to the Company's methods for managing credit risk during the period ended September 30, 2021.

Liquidity Risk

Liquidity risk is the risk that the Company will have sufficient cash resources to meet its financial obligations as they come due. The Company did not generate cash flows from its principal operations and relied on its cash balance to pay its liabilities. Management ensures it maintains sufficient cash on hand for continued operations.

There have been no changes to management's methods for managing liquidity risk since December 31, 2020. The Company has working capital of \$74.6 million as of September 30, 2021 (September 30, 2020 - \$116.9 million) and in management's judgment, the Company has sufficient working capital to continue to fund its operations and to pay its liabilities for the next fiscal year. If required, the company could sell a portion of its public company investments to supplement the liquidity requirements.

Market Risk

Market risk is comprised of equity price risk, foreign currency risk and interest rate risk. The Company's exposure to these risks is described below.

Equity Price Risk

Equity price risk is the risk that the fair value of, or future cash flows from, the Company's financial instruments will significantly fluctuate due to changes in stock market prices. All securities present a risk of loss of capital. Any equity and derivative instrument that the Company may hold is susceptible to market price risk arising from uncertainties about future prices of the instruments. Management moderates this risk through a careful selection of securities and other financial instruments with the parameters of the Company's investment strategy. The maximum risk resulting from financial instruments is equivalent to their fair value.

The most significant exposure for the Company to equity price risk arises from its investment in securities of publicly and privately traded companies. As at September 30, 2021, for securities of publicly traded companies, had the prices on respective stock exchanges for those securities increased or decreased by 10%, with all other variables held constant, net assets would have increased or decreased, respectively, by approximately \$13.8 million (December 31, 2020 - \$9.9 million) or approximately 6.0% (December 31, 2020 - 4.7%) of total assets. In practice, the actual results may differ. Management is unable to meaningfully quantify any correlation of the price of its private company investment to changes in a benchmark index.

There has been no change in the Company's long-term investment strategy, despite the COVID-19 pandemic.

Foreign Currency Risk

Foreign currency risk is the risk that fluctuations in the rates of exchange on foreign currency would impact the Company's future cash flows. The Company has minimal exposure to foreign exchange fluctuations as it only has an immaterial amount of cash held in a United States ("US") dollar bank account. The Company has no other assets or liabilities denominated in US dollars. There have been no changes in management's foreign currency risk management strategies for the year.

Interest Rate Risk

Interest rate risk is the risk that the fair value of future cash flows from a financial instrument will fluctuate due to changes in market interest rates. The Company's exposure to interest rate risk relates to its ability to earn interest income on cash and cash equivalents. The fair value of the Company's cash and cash equivalents affected by changes of interest rates is minimal. There have been no changes to management's strategies to mitigate interest rate risk for the year.

DISCLOSURE CONTROLS AND PROCEDURES

The Company's disclosure controls and procedures are designed to provide reasonable assurance that (a) material information relating to the Company is made known to the CEO and the Chief Financial Officer by others, particularly during the period in which the annual filings are being prepared, and (b) information required to be disclosed by the Company in its annual filings, interim filings or other reports filed or submitted by it under securities legislation is recorded, processed, summarized and reported within the time periods specified in securities legislation. Based on their evaluation, the CEO and the Chief Financial Officer have concluded that as of September 30, 2021, the Company's disclosure controls and procedures were effective.

INTERNAL CONTROL OVER FINANCIAL REPORTING

The Company's internal control over financial reporting is designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with IFRS. The Company's management is responsible for establishing and maintaining adequate internal control over financial reporting.

All internal control systems have inherent limitations and may become inadequate because of changes in conditions. Therefore, even those systems determined to be effective can provide only reasonable assurance with respect to financial statement preparation and presentation.

Management has evaluated the effectiveness of the Company's internal control over financial reporting based on the Internal Control - Integrated Framework (COSO 2013 Framework) published by The Committee of Sponsoring Organizations of the Treadway Commission. Based on their evaluations as of September 30, 2021, the CEO and the Chief Financial Officer have concluded that, as of September 30, 2021, the Company's internal control over financial reporting is effective in providing reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with IFRS.

During the third quarter of 2021, there have been no changes in the Company's internal control over financial reporting that have materially affected, or are reasonably likely to materially affect, the Company's internal control over financial reporting.

OUTSTANDING SHARE DATA

The Company's issued and outstanding capital as at September 30, 2021 consisted of 26,971,411 multiple voting shares, 15,685,014 subordinate voting shares and 15,559,500 Founder Warrants. As at September 30, 2021, the Company had 428,884 RSUs outstanding. RSUs are share settled in subordinate voting shares.

The Company's issued and outstanding capital as at November 3, 2021 consisted of 26,971,411 multiple voting shares, 15,628,470 subordinate voting shares, 15,559,500 Founder Warrants and 428,884 RSUs.